A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients With Resectable Cutaneous Squamous Cell Carcinoma (cSCC)
ASTRO Poster Library, Shlomo Koyfman,
408912
Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
ASTRO Poster Library, Michael Gibson,
409018
Weekly paclitaxel, carboplatin, and cetuximab (PCC) as treatment for recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on immune checkpoint inhibitors (ICI): a retrospective analysis
ASTRO Poster Library, Priyanka Bhateja,
408975
Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients With PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study
ASTRO Poster Library, Nabil Saba,
408967
FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
ASTRO Poster Library, Julie Bauman,
408919